These findings support that targeting the solTNF-TNFR1 signaling pathway would be an attractive treatment strategy and potentially even better than non-selective TNF therapy for patients with growing AAA, which is highly desired. This evidence concerns the gene TNFRSF1A and triple-A syndrome.